Patents by Inventor Rene de Waal Malefyt

Rene de Waal Malefyt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210363243
    Abstract: Provided herein are methods of treating cancer or infection, which comprise administering to a human patient in need thereof: (a) an anti-human PD-1 monoclonal antibody or antigen binding fragment thereof; (b) an anti-human LAG3 monoclonal antibody or antigen binding fragment thereof; and (c) an anti-human TIGIT monoclonal antibody or antigen binding fragment thereof. Also provided are pharmaceutical compositions and kits containing such agents for the treatment of cancer or infection.
    Type: Application
    Filed: January 31, 2019
    Publication date: November 25, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mingmei Cai, Rene de Waal Malefyt, Laurence Fayadat-Dilman, Ying Li, Ruban Mangadu, Uyen Phan
  • Patent number: 11045547
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: June 29, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Rene De Waal Malefyt, Laurence Fayadat-Dilman, Linda Liang
  • Patent number: 10898571
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: January 26, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
  • Publication number: 20190270802
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and an antagonist of IL-27, and the use of the combination therapies for the treatment of cancer. In certain embodiments, the PD-1 antagonist is an anti-human PD-1 antibody, or antigen binding fragment thereof. In further embodiments, the anti-PD-1 antibody is pembrolizumab. In certain embodiments the antagonist of IL-27 is an anti-IL-27 antibody, or antigen binding fragment thereof, an anti-p28 antibody, or antigen binding fragment thereof, or an anti-EBI-3 antibody, or antigen binding fragment thereof. Also provided are medicaments, compositions, and kits comprising a PD-1 antagonist and an IL-27 antagonist for use in treating cancer.
    Type: Application
    Filed: October 19, 2017
    Publication date: September 5, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Nataliya Tovbis Shifrin, Rene de Waal Malefyt
  • Publication number: 20190091332
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Application
    Filed: December 7, 2018
    Publication date: March 28, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
  • Publication number: 20190083614
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Application
    Filed: December 4, 2018
    Publication date: March 21, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
  • Publication number: 20190083615
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Application
    Filed: December 5, 2018
    Publication date: March 21, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
  • Patent number: 10188730
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAGS as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: January 29, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
  • Publication number: 20180369375
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Application
    Filed: December 13, 2016
    Publication date: December 27, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Rene De Waal Malefyt, Laurence Fayadat-Dilman, Linda Liang
  • Publication number: 20170290914
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Application
    Filed: August 17, 2015
    Publication date: October 12, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
  • Publication number: 20170267759
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAGS as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Application
    Filed: April 7, 2017
    Publication date: September 21, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
  • Patent number: 9732151
    Abstract: The present invention relates to biomarker responsive to treatment with an anti-Thymic Stromal Lymphopoietin (TSLP) antibody.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: August 15, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Maribel Beaumont, Jeanine D. Mattson, Jennifer R. Louten, Terrill K. McClanahan, Rene de Waal Malefyt
  • Patent number: 9422355
    Abstract: Purified genes encoding cytokines from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: August 23, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: J. Fernando Bazan, Rene de Waal Malefyt, Yong-Jun Liu, Vassili Soumelis
  • Publication number: 20140335094
    Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: July 14, 2014
    Publication date: November 13, 2014
    Inventors: Birgit Oppmann, Rene de Waal Malefyt, Donna M. Rennick, Robert A. Kastelein, Maria T. Wiekowski, Sergio A. Lira, Satwant K. Narula
  • Publication number: 20140302061
    Abstract: The present invention relates to biomarker responsive to treatment with a TSLP antagonist.
    Type: Application
    Filed: October 31, 2012
    Publication date: October 9, 2014
    Inventors: Maribel Beaumont, Jeanine D. Mattson, Jennifer R. Louten, Terrill K. McClanahan, Rene de Waal Malefyt
  • Patent number: 8791242
    Abstract: The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: July 29, 2014
    Assignee: Intervet Inc.
    Inventors: Jeanine D. Mattson, Daniel M. Gorman, Rene de Waal Malefyt, Mohamad A. Morsey
  • Publication number: 20140170658
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 19, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JACQUELINE C. TIMANS, STEFAN KARL-HEINZ PFLANZ, ROBERT A. KASTELEIN, J. FERNANDO BAZAN, DONNA RENNICK, RENE DE WAAL MALEFYT, JEANNE CHEUNG
  • Publication number: 20140141011
    Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
    Type: Application
    Filed: October 8, 2013
    Publication date: May 22, 2014
    Applicant: SCHERING CORPORATION
    Inventors: LEONARD G. PRESTA, RENE DE WAAL MALEFYT
  • Patent number: 8691953
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
  • Publication number: 20140093875
    Abstract: Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: December 2, 2013
    Publication date: April 3, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Pedro A. Reche-Gallardo, Vassili Soumelis, Yong-Jun Liu, Rene de Waal Malefyt, J. Fernando Bazan, Robert A. Kastelein